Publications by authors named "R Ennis"
Background: Tumor suppressors are well known drivers of cancer invasion and metastasis in metastatic castration sensitive prostate cancer (mCSPC). However, oncogenes are also known to be altered in this state, however the frequency and prognosis of these alterations are unclear. Thus, we aimed to study the spectrum of oncogene mutations in mCSPC and study the significance of these alteration on outcomes.
View Article and Find Full Text PDFA developmental milestone that both contributes to and facilitates a successful transition into adulthood is the ability to drive. Yet only one in three autistic adolescents successfully obtain a driver's license by age 21 compared to over three-fourths of non-autistic adolescents. Of those who receive their license, there is inconsistency in driving attitudes, experiences and skills.
View Article and Find Full Text PDFBackground: Number of organ transplant recipients continues to rise worldwide with increasing accessibility and growing advancements in transplant medicine. Transplant patients have at least a two-to-four fold higher risk of developing cancer compared to the general population. As the prevalence of transplant patients increases, a growing number of these patients are expected to present with concurrent conditions such as cancer, requiring more complex and interdisciplinary care.
View Article and Find Full Text PDFArticle Synopsis
- Plasma p-tau217 is identified as a promising blood-based marker for detecting Alzheimer Disease (AD) pathology, particularly in memory clinic patients undergoing lumbar punctures.
- A study involving 108 participants found that plasma p-tau217 levels were significantly higher in those with detected amyloid (Aβ) pathology compared to those without, indicating its strong potential for diagnosis.
- The analysis showed that plasma p-tau217 had excellent performance metrics for Aβ detection (AUC: 0.91), outperforming other biomarkers and suggesting it could be a reliable tool in Alzheimer's diagnostics.
Background: Alterations in the PIK3/Akt/mTOR pathway are commonly seen in metastatic castration-sensitive prostate cancer (mCSPC), however their role in outcomes is unknown. We aim to evaluate the prognostic significance as well as the genetic landscape of PIK3/Akt/mTOR pathway alteration in mCSPC.
Methods: Fourhundred and seventy-two patients with mCSPC were included who underwent next generation sequencing.